Drug class
Small Interfering RNA; Transthyretin-directed RNA Interaction
Mechanism of action
Patisiran is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
General use cases
- Amyloid Neuropathies, Familial
- the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
